Dashboard
Manage Tickers

FULCFulcrum Therapeutics, Inc.

Nasdaq fulcrumtx.com


$ 8.64 $ 0.09 (1.05 %)    

Monday, 09-Sep-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 8.63
$ 8.82
$ 8.61 x 106
-- x --
$ 8.51 - $ 9.29
$ 3.14 - $ 13.70
994,417
na
538.52M
$ 1.50
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 02-27-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-09-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 03-03-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-10-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 03-04-2021 12-31-2020 10-K
16 11-10-2020 09-30-2020 10-Q
17 08-11-2020 06-30-2020 10-Q
18 05-13-2020 03-31-2020 10-Q
19 03-05-2020 12-31-2019 10-K
20 11-14-2019 09-30-2019 10-Q
21 08-26-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

fulcrum-therapeutics-upgraded-bofa-debates-pivotal-study-success-for-losmapimod-in-rare-genetic-muscle-disease
Fulcrum Therapeutics Upgraded: BofA Debate...
09/09/2024 18:28:05

BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystroph...

b-of-a-securities-upgrades-fulcrum-therapeutics-to-neutral-raises-price-target-to-10
B of A Securities Upgrades Fulcrum Therape...
09/09/2024 11:42:17

B of A Securities analyst Tazeen Ahmad upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Underperform to Neutral and raises t...

8-health-care-stocks-with-whale-alerts-in-todays-session
8 Health Care Stocks With Whale Alerts In ...
08/01/2024 17:35:24

hc-wainwright--co-reiterates-buy-on-fulcrum-therapeutics-maintains-17-price-target
HC Wainwright & Co. Reiterates Buy on Fulc...
08/01/2024 13:14:09

HC Wainwright & Co. analyst Andrew Fein reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and maintains $17 price...

fulcrum-therapeutics-q2-eps-totals-087-compared-with-038-loss-yoy-company-exits-quarter-with-cash-and-equivalents-worth-2738m
Fulcrum Therapeutics Q2 EPS Totals $0.87 C...
07/31/2024 11:08:26

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly earnings of $0.87 per share his is a 328.95 percent increase over losses ...

top-3-health-care-stocks-that-should-keep-you-up-at-night-this-quarter
Top 3 Health Care Stocks That Should Keep ...
07/16/2024 12:16:01

cantor-fitzgerald-reiterates-overweight-on-fulcrum-therapeutics-maintains-23-price-target
Cantor Fitzgerald Reiterates Overweight on...
07/10/2024 14:10:23

Cantor Fitzgerald analyst Kristen Kluska reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and maintains $23 p...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
06/11/2024 17:35:23

cantor-fitzgerald-initiates-coverage-on-fulcrum-therapeutics-with-overweight-rating-announces-price-target-of-23
Cantor Fitzgerald Initiates Coverage On Fu...
05/20/2024 11:46:17

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight rating a...

goldman-sachs-upgrades-fulcrum-therapeutics-to-buy-raises-price-target-to-15
Goldman Sachs Upgrades Fulcrum Therapeutic...
05/14/2024 12:40:06

Goldman Sachs analyst Corinne Jenkins upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Neutral to Buy and raises the price t...

hc-wainwright--co-reiterates-buy-on-fulcrum-therapeutics-maintains-17-price-target
HC Wainwright & Co. Reiterates Buy on Fulc...
05/14/2024 11:09:55

HC Wainwright & Co. analyst Andrew Fein reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and maintains $17 price...

oppenheimer-maintains-outperform-on-fulcrum-therapeutics-lowers-price-target-to-14
Oppenheimer Maintains Outperform on Fulcru...
05/14/2024 09:21:07

Oppenheimer analyst Matthew Biegler maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Outperform and lowers the price targ...

deep-dive-into-fulcrum-therapeutics-stock-analyst-perspectives-4-ratings
Deep Dive Into Fulcrum Therapeutics Stock:...
05/13/2024 21:01:14

goldman-sachs-upgrades-fulcrum-therapeutics-to-buy-announces-15-price-target
Goldman Sachs Upgrades Fulcrum Therapeutic...
05/13/2024 20:22:24

Goldman Sachs analyst Corinne Jenkins upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Neutral to Buy and announces $15 pric...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
05/13/2024 12:06:42

fulcrum-therapeutics-expects-cash-balance-of-2133m-along-with-upfront-payment-of-800m-expected-to-fund-its-operating-requirements-into-2027
Fulcrum Therapeutics Expects Cash Balance ...
05/13/2024 11:05:06

fulcrum-therapeutics-q1-2024-gaap-eps-043-beats-044-estimate
Fulcrum Therapeutics Q1 2024 GAAP EPS $(0....
05/13/2024 11:01:57

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of ...

Core News & Articles
Fulcrum Therapeutics Announces License Agr...
05/13/2024 10:04:22

― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. c...

fulcrum-therapeutics-announces-publication-of-results-from-phase-2b-clinical-trial-of-losmapimod-in-facioscapulohumeral-muscular-dystrophy-in-the-lancet-neurology
Fulcrum Therapeutics Announces Publication...
05/08/2024 12:13:43

― Phase 2b ReDUX4 clinical trial indicates improvements in functional, structural, and patient-reported outcomes; findings info...

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
03/29/2024 17:35:25

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION